![](/img/cover-not-exists.png)
1223 NO EARLY VIROLOGIC BREAKTHROUGH OBSERVED WITH THE HCV NS3 PROTEASE INHIBITOR BMS-650032 IN MULTIPLE DOSE MONOTHERAPY STUDIES AND PHASE 2A COMBINATION STUDIES WITH PEGIFNα/RBV
McPhee, F., Sheaffer, A., Yu, F., Lee, M., Chaniewski, S., Falk, P., Pasquinelli, C., Llasamo, C., Hughes, E., Hernandez, D.Volume:
54
Language:
english
Journal:
Journal of Hepatology
DOI:
10.1016/S0168-8278(11)61225-7
Date:
March, 2011
File:
PDF, 41 KB
english, 2011